Compare SIF & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIF | TLSA |
|---|---|---|
| Founded | 1913 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.1M | 124.0M |
| IPO Year | 1995 | 2017 |
| Metric | SIF | TLSA |
|---|---|---|
| Price | $20.21 | $1.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 156.7K | ★ 713.0K |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 86.67 | N/A |
| EPS | ★ 0.71 | N/A |
| Revenue | ★ $111,212,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $27.25 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.88 | $0.87 |
| 52 Week High | $29.00 | $2.35 |
| Indicator | SIF | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 37.00 | 60.44 |
| Support Level | $19.05 | $1.14 |
| Resistance Level | $22.02 | $1.45 |
| Average True Range (ATR) | 2.23 | 0.10 |
| MACD | -0.98 | 0.02 |
| Stochastic Oscillator | 23.32 | 91.81 |
SIFCO Industries Inc produces forgings, sub-assemblies, and machined components for the Aerospace and Energy markets. Its services include forging, heat treating, machining, surface treatment, non-destructive testing, and sub-assembly of forged components. The company manufactures envelopes and precision forgings, as well as rough and finished machined parts, serving OEMs, Tier 1 and Tier 2 suppliers, and aftermarket providers across Aerospace, Defense, Energy, and Commercial Space. Its Products are made from steel, high-temperature alloys, nickel alloys, titanium, and aluminum, and include components for aircraft and industrial gas turbine engines, airframe structures, landing gear, wheels and brakes, helicopter rotating parts, and other commercial and industrial applications.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.